Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018178295) STABLE HOT-MELT EXTRUDATE CONTAINING VALSARTAN AND SACUBITRIL
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/178295 International Application No.: PCT/EP2018/058207
Publication Date: 04.10.2018 International Filing Date: 29.03.2018
IPC:
A61K 9/14 (2006.01) ,A61K 9/20 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
Applicants:
ALFRED E. TIEFENBACHER (GMBH & CO. KG) [DE/DE]; Van-der-Smissen-Straße 1 22767 Hamburg, DE
Inventors:
RALLABANDI, Bala Ramesha Chary; IN
PRATHAP, Vamshi Ramana; IN
GOLLAPUDI, Rajesh Krishna Mohan; IN
SCHLEHAHN, Hendrik; DE
RUCHATZ, Dieter; DE
Agent:
HAMM&WITTKOPP PATENTANWÄLTE PARTMBB; Jungfernstieg 38 20354 Hamburg, DE
Priority Data:
20171101167731.03.2017IN
62/513,60501.06.2017US
Title (EN) STABLE HOT-MELT EXTRUDATE CONTAINING VALSARTAN AND SACUBITRIL
(FR) EXTRUDAT THERMOFUSIBLE STABLE CONTENANT DU VALSARTAN ET DU SACUBITRIL
Abstract:
(EN) The present invention relates to a solid unit dosage form for oral administration (tablet or granules) containing a solid dispersion of valsartan and sacubitril in a polymeric matrix. The solid dispersion is prepared by hot-melt extrusion and may contain the active ingredients preferably in a non-crystalline state. LCZ696, (pseudo)polymorphic forms thereof as well as the individual drugs, e.g. valsartan disodium and sacubitril monosodium, may be subjected to the hot-melt extrusion process.
(FR) La présente invention concerne une forme posologique unitaire solide pour administration orale (comprimé ou granules) contenant une dispersion solide de valsartan et de sacubitril dans une matrice polymère. La dispersion solide est préparée par extrusion par thermofusion et peut contenir les ingrédients actifs de préférence dans un état non cristallin. LCZ696, formes polymorphes (pseudo) de celui-ci ainsi que les médicaments individuels, par exemple le valsartan disodique et le sacubitril monosodique, peuvent être soumis au processus d'extrusion par thermofusion.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)